Jung Park, MD
Neurology · Denver, CONPI 1609216563
Payments from drug & device makers
Across 20 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$79
- UCB, Inc.$61
- Pfizer$36
- Eisai Inc.$28
- Acorda Therapeutics, Inc$24
- Mallinckrodt Hospital Products Inc.$24
- plus $138 from 8 others
What the payments were for
- Speaking & faculty fees$246%
- Food & beverage$36694%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 4 | $79 |
| UCB, Inc. | 2 | $61 |
| Pfizer | 2 | $36 |
| Eisai Inc. | 2 | $28 |
| Acorda Therapeutics, Inc | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $22 |
| Novartis | 1 | $21 |
| Amgen | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Merz Pharmaceuticals, LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Lilly USA, LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$390 in reported general payments places this provider in the 35th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 55 | $47,613 |
| Lacosamide | 16 | $1,723 |
| Gabapentin | 57 | $1,195 |
| Pregabalin | 32 | $656 |
| Duloxetine Hcl | 25 | $519 |
| Amitriptyline Hcl | 18 | $498 |
| Primidone | 11 | $420 |
| Levetiracetam | 16 | $392 |
| Nortriptyline Hcl | 11 | $353 |
| Methocarbamol | 11 | $169 |
| Escitalopram Oxalate | 14 | $50 |
Paid to pharmacies, not to this prescriber.
Other neurology in Denver
- Adam WolffDenver$2.4M
- Justin MoonDenver$1.4M
- Bennett MachanicDenver$860K
- Michael AmentDenver$457K
- Jinny TaveeDenver$225K
- Matthew WongDenver$190K
- Shankar PerumalDenver$99K
- Andrew WhiteDenver$72K
- Enrique AlvarezAurora$14.3M
- Rajeev KumarEnglewood$14.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.